论文部分内容阅读
目的:分析子宫托治疗对症状性盆腔器官脱垂(POP)患者广泛性焦虑障碍的影响。方法:本研究为前瞻性队列研究,纳入北京协和医院妇科2018年12月至2020年1月≥18岁213例因POP行子宫托治疗的患者。子宫托试戴成功的标准定义为戴托2周主观症状改善满意并愿意继续戴托;或更换新的子宫托后再次试戴2周效果满意并愿意继续戴托。采用广泛性焦虑障碍量表(GAD-7)对163例试戴成功患者和50例失败患者进行子宫托治疗前后的焦虑评估,评分为10分及以上为中重度焦虑,定义为焦虑障碍,并继续对成功组进行3个月随访。比较两组治疗前后焦虑障碍患病率及焦虑障碍GAD-7评分差异。结果:研究对象年龄为(67.4±9.2)岁。治疗前,治疗成功组(34/163,20.9%)和失败组(10/50,20.0%)焦虑障碍患病率差异无统计学意义(n P=0.896)。对完成随访患者进一步分析显示,焦虑障碍组(34例)和非焦虑障碍组(129例)的基本特征和临床特征差异均无统计学意义(n P>0.05)。子宫托治疗3个月后,焦虑障碍的患病率从治疗前20.9%(34例)降至治疗后3.7%(6例)(n P<0.001)。治疗前,焦虑障碍患者GAD-7评分n M(n Q1,n Q3)为16.0(12.5,21.0),降至治疗后的1.0(0,4.0)(n P0.05). After 3 months of the pessary treatment for those patients using the pessary treatment, the prevalence of anxiety disorders dropped to 3.7% (6/163) from 20.9% (n P<0.001). The GAD-7 score of patients with anxiety disorders decreased from a median of 16.0 (12.5, 21.0) before the treatment to 1.0 (0, 4.0) after the treatment, and the difference was statistically significant (n P<0.001).n Conclusion:Around 20% POP patients receiving pessary treatment had the moderate or severe general anxiety disorder. After 3 months of using the pessary treatment, the prevalence of anxiety disorders in POP patients had dropped significantly.